Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fate Therapeutics (FATE) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Fate Therapeutics (FATE) over the last 14 years, with Q3 2025 value amounting to $119.0 million.

  • Fate Therapeutics' Shares Outstanding (Weighted Average) rose 104.4% to $119.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $119.0 million, marking a year-over-year increase of 104.4%. This contributed to the annual value of $113.7 million for FY2024, which is 1552.06% up from last year.
  • Latest data reveals that Fate Therapeutics reported Shares Outstanding (Weighted Average) of $119.0 million as of Q3 2025, which was up 104.4% from $118.5 million recorded in Q2 2025.
  • Fate Therapeutics' Shares Outstanding (Weighted Average)'s 5-year high stood at $119.0 million during Q3 2025, with a 5-year trough of $93.4 million in Q1 2021.
  • Over the past 5 years, Fate Therapeutics' median Shares Outstanding (Weighted Average) value was $98.4 million (recorded in 2023), while the average stood at $103.4 million.
  • As far as peak fluctuations go, Fate Therapeutics' Shares Outstanding (Weighted Average) skyrocketed by 2311.98% in 2021, and later surged by 90.23% in 2025.
  • Over the past 5 years, Fate Therapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $94.7 million in 2021, then rose by 2.19% to $96.8 million in 2022, then increased by 1.64% to $98.4 million in 2023, then grew by 15.52% to $113.7 million in 2024, then rose by 4.67% to $119.0 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $119.0 million for Q3 2025, versus $118.5 million for Q2 2025 and $118.4 million for Q1 2025.